Expand ADCT Menu
ADCT MENU

ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

Charts for Today's Stock Price and Implied Volatility in Adc Therapeutics SA Common Shares

7-Jan-2026

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for ADCT by Theoretical Edge and Win Rates

Sentiment

Trading Statistics

Key Ratios

Adc Therapeutics SA Common Shares (ADCT) Frequently Asked Questions

What does Adc Therapeutics SA Common Shares do?

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

What symbol and exchange does Adc Therapeutics SA Common Shares shares trade?

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

What is Adc Therapeutics SA Common Shares stock price doing today?

As of January 7, 2026, ADCT stock price climbed to $3.65 with 808,028 million shares trading.

What is Adc Therapeutics SA Common Shares's Beta?

ADCT has a beta of 1.89, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.13 to the broad based SPY ETF.

How much is Adc Therapeutics SA Common Shares worth?

ADCT has a market cap of $452.15 million. This is considered a Small Cap stock.

How much money does Adc Therapeutics SA Common Shares make?

Last quarter Adc Therapeutics SA Common Shares reported $16 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-89,202 and exceeded earnings estimates by $.19.

What is the highest and lowest price Adc Therapeutics SA Common Shares traded in the last 3 year period?

In the last 3 years, ADCT traded as high as $6.04 and as low as $.36.

What are the top ETFs holding Adc Therapeutics SA Common Shares?

The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IWM, IWO, IBB, VTWO, VFMO.

Is Adc Therapeutics SA Common Shares (ADCT) a good investment?

ADCT has outperformed the market in the last year with a price return of +82.5% while the SPY ETF gained +18.4%. However, in the short term, ADCT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.3% vs +3.4% return in SPY. But in the last 2 weeks, ADCT shares have fared better than the market returning +3.4% compared to SPY -0.1%.

What are the support and resistance levels for Adc Therapeutics SA Common Shares (ADCT)?

ADCT support price is $3.36 and resistance is $3.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.

Market Data Delayed 15 Minutes